Rare Renal Indications
JSPRJasper TherapeuticsCatalyst overview
Research summary
This catalyst tracks a Phase 2 data readout for Vensobafusp Alfa (KP-104) (Dual Complement Inhibitor) in Rare Renal Indications. The expected timing is based on the latest available company guidance and may change.
08/14/26:- Phase 2 basket trial Stage 1 interim data will be reported in Q4 2026.
Verification
Confirm timing and program details against the company announcement or filing.